Table 2.
Tilt table test data of ME/CFS participants and healthy controls.
| Group 1 HC with norm HR/BP N = 44 |
Group 2 ME/CFS with norm HR/BP N = 247 |
Group 3 ME/CFS with dOH N = 62 |
Group 4 ME/CFS with POTS N = 120 |
Group 1 vsGroup 2P | Group 2 vsGroup 3P | Group 2 vsGroup 4P | Group 3 vsGroup 4P | |
|---|---|---|---|---|---|---|---|---|
| HR supine (bpm) | 65 (13) | 70 (10) | 71 (11) | 77 (14) | <0.005 | <0.0005 | <0.005 | |
| HR end-tilt (bpm) | 83 (15) | 88 (12) | 93 (14) | 117 (16) | <0.01 | <0.0005 | <0.0005 | |
| SBP supine (mmHg) | 132 (14) | 135 (17) | 142 (17) | 132 (15) | <0.005 | <0.0005 | ||
| SBP end-tilt (mmHg) | 125 (13) | 133 (17) | 119 (14) | 126 (15) | <0.01 | <0.0005 | <0.0005 | <0.01 |
| DBP supine (mmHg) | 78 (7) | 79 (9) | 79 (9) | 78 (8) | ||||
| DBP end-tilt (mmHg) | 81 (8) | 86 (9) | 79 (8) | 86 (9) | <0.005 | <0.0005 | <0.0005 | |
| PetCO2 supine (mmHg) | 37 (35–39) | 37 (35–38) | 37 (35–39) | 36 (34–38) | ||||
| PetCO2 end-tilt (mmHg) | 36 (34–38) | 32 (28–35) | 32 (28–35) | 26 (23–31) | <0.0005 | <0.0005 | <0.0005 | |
| CBF supine (ml/min) | 625 (79) | 613 (108) | 609 (108) | 623 (97) | ||||
| CBF mid-tilt (ml/min) | 594 (77) | 505 (107) | 460 (85) | 462 (85) | <0.0005 | <0.005 | <0.001 | |
| CBF mid-tilt %change | −5.1 (2.6)% | −19.1 (10.2)% | −25.4 (6.7)% | −26.1 (6.5)% | <0.0005 | <0.0005 | <0.001 | |
| CBF end-tilt (ml/min) | 581 (76) | 467 (102) | 440 (84) | 443 (76) | <0.0005 | |||
| CBF end-tilt %change | −6.7 (3.1)% | −23.6 (10.3)% | −27.7 (6.0)% | −28.9 (5.8)% | <0.0005 | <0.0005 | <0.0005 |
BP: blood pressure; DBP: diastolic blood pressure; CBF: cerebral blood flow; dOH: delayed orthostatic hypotension; HR: heart rate; HC: healthy controls; norm: normal; PetCO2: end-tidal CO2 pressure; POTS: postural orthostatic tachycardia syndrome; SBP: systolic blood pressure; %change: percent change from supine data.
All within group supine values differ from end-tilt values at P < 0.001 except for SBP and DBP in HC which differ at P < 0.005, and DBP in dOH which did not differ.